GlassScriptPhysician profile
Niraj H Mehta
NPI 1598919243
$16,440.79
in general payments reported to CMS, 2019-2025
38 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 85% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.52 · 2020: $539 · 2021: $7,293 · 2022: $1,567 · 2023: $4,431 · 2024: $1,350 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,072 · Honoraria: $1,200 · Consulting Fee: $525 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,072.24 |
| Honoraria | $1,200.00 |
| Consulting Fee | $525.00 |
| Education | $164.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $5,952.71 | 2020-2025 | Optune, Optune Lua (Novottf-200t), Optune Gio |
| Myriad Genetic Laboratories, INC. | $2,252.41 | 2021-2025 | Prolaris, Precisetumor |
| Painteq LLC | $1,851.56 | 2021-2023 | Painteq |
| Janssen Biotech, INC. | $1,463.75 | 2020-2025 | Erleada, Akeega, Balversa |
| Pfizer INC. | $554.61 | 2021-2025 | |
| Isoray, INC | $546.52 | 2023-2024 | Brachytherapy Source |
| Sumitomo Pharma America, INC. | $519.78 | 2023-2025 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $496.34 | 2019-2025 | Spaceoar Vue System - 10ml |
| Astellas Pharma US INC | $469.85 | 2021-2025 | Xtandi |
| Brainlab, INC. | $317.68 | 2019-2025 | Brainlab, INC. |
| Myovant Sciences INC. | $251.55 | 2021-2022 | |
| Reflexion Medical, INC. | $193.85 | 2021-2024 | Reflexion Medical Radiotherapy System |
| Bayer Healthcare Pharmaceuticals INC. | $182.79 | 2024-2025 | |
| Abbvie INC. | $171.74 | 2022-2024 | |
| Daiichi Sankyo INC. | $122.79 | 2024 | Enhertu |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $121.80 | 2023 | Quviviq |
| Teleflex LLC | $87.08 | 2025 | Barrigel |
| Telix Pharmaceuticals | $85.47 | 2023-2025 | Illuccix |
| Palette Life Sciences, INC. | $81.23 | 2022 | |
| Blue Earth Diagnostics | $68.30 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $65.49 | 2020-2021 | |
| Novo Nordisk INC | $65.31 | 2020 | |
| Cashflow Solutions, LLC | $60.30 | 2024-2025 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Bioprotect Medical, INC. | $46.18 | 2025 | Bioprotect Balloon Implant System |
| Coloplast Corp | $44.71 | 2021 | |
| Accuray Incorporated | $43.81 | 2021 | |
| Novartis Pharmaceuticals Corporation | $41.61 | 2021-2024 | |
| Napo Pharmaceuticals INC | $35.79 | 2025 | Gelclair Concentrated Oral Gel |
| Merck Sharp & Dohme LLC | $31.59 | 2024 | Keytruda |
| Foundation Medicine, INC. | $31.45 | 2020 | |
| Karyopharm Therapeutics INC. | $27.06 | 2021 | |
| Dendreon Pharmaceuticals LLC | $26.02 | 2025 | Provenge |
| Progenics Pharmaceuticals, INC. | $24.52 | 2023 | Pylarify |
| Verity Pharmaceuticals INC. | $22.83 | 2020 | |
| Axonics, INC. | $22.75 | 2022 | |
| Kyowa Kirin, INC. | $22.47 | 2019 | |
| Tactile Systems Technology INC | $19.98 | 2023 | Flexitouch Plus, Entre Plus |
| Q Biomed INC. | $17.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.